Omnicell (NASDAQ:OMCL) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a report released on Monday.

A number of other equities analysts have also commented on OMCL. JPMorgan Chase & Co. cut their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Wells Fargo & Company cut their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Benchmark restated a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Bank of America cut their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Omnicell presently has a consensus rating of “Hold” and an average price target of $51.00.

Omnicell Price Performance

OMCL stock opened at $35.14 on Monday. The stock has a 50-day simple moving average of $39.63 and a 200-day simple moving average of $42.83. The firm has a market cap of $1.64 billion, a P/E ratio of 130.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.75.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, equities analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Omnicell by 22.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company’s stock valued at $5,306,000 after acquiring an additional 21,847 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Omnicell by 286.4% in the 4th quarter. Squarepoint Ops LLC now owns 149,717 shares of the company’s stock worth $6,665,000 after buying an additional 110,966 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Omnicell by 44.2% in the 4th quarter. Two Sigma Investments LP now owns 141,738 shares of the company’s stock valued at $6,310,000 after buying an additional 43,471 shares during the period. Toronto Dominion Bank bought a new stake in shares of Omnicell during the 4th quarter valued at about $30,637,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Omnicell during the 4th quarter valued at about $101,000. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.